tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inventiva initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Inventiva (IVA) with a Buy rating and $10 price target The firm thinks the company’s oral pan-PPAR agonist lanifibranor will reduce insulin resistance, lower hepatic inflammation, and improve fibrosis in metabolic dysfunction-associated steatohepatitis, with improved tolerability over current PPAR agonists and MASH therapies. TD is positive on the topline data guided for the second half of 2026.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1